22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery

Business by 2FIRSTS.ai
Dec.06.2023
22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery
22nd Century Group Inc's stock price fell 12.26% from its previous closing price of 0.26, despite a 10.19% increase in the past five trading days.

According to a report by Zacks Investment Research, the stock price of 22nd Century Group Inc (NASDAQ: XXII) has dropped by 12.26 percentage points, closing at 0.26 below its previous closing price.

 

Despite this, the company's stock price has risen by 10.19% over the past five trading days. The VLN tobacco products of 22nd Century Group have been certified by the US FDA as reduced-risk tobacco products for the first time.

 

The question of whether the stock of 22nd Century Group Inc. (NASDAQ: XXII) is worth investing in has received mixed market reactions. The company's stock has experienced a 10.19% increase over the past week, but has seen declines of 50.64% and 84.90% over the past 30 days and 90 days respectively.

 

The performance of 22nd Century Group Inc. (NASDAQ: XXII) in recent times has been unable to surpass its 52-week low, resulting in the company sustaining a loss of -98.77% over a period of time. However, in the past five trading days, the stock has shown some recovery, reaching a gain of +10.19%. Nonetheless, it has still dropped by 98.43% compared to the 200-day moving average of 0.3131 USD.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JT launches limited-edition Ploom AURA front panels; two go on sale, three offered via prize draw
JT launches limited-edition Ploom AURA front panels; two go on sale, three offered via prize draw
Japan Tobacco (JT) has rolled out an Ichiro Yamaguchi collaboration under its Ploom AURA “SENSATIONAL” campaign, using a combined marketing push—limited sales, a prize draw, video content distribution and in-store displays—to release five front panels and two branded accessories. Two panels will go on sale from Jan. 27, while the remaining panels and accessories will be distributed through a draw running from Jan. 19 to Feb. 28.
Jan.19 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Nicaragua’s Health Ministry reaffirms Resolution No. 334-2021, maintaining a total ban on vaping and e-cigarette sales
Nicaragua’s Health Ministry reaffirms Resolution No. 334-2021, maintaining a total ban on vaping and e-cigarette sales
Nicaragua’s Ministry of Health (MINSA) issued an official statement on January 2, 2026 reaffirming the validity of Ministerial Resolution No. 334-2021, which absolutely bans the use and commercialization of electronic nicotine delivery systems known as “vapeadores” or e-cigarettes.
Jan.04 by 2FIRSTS.ai
Singapore Health Minister Ong Ye Kung receives SEATCA award for tobacco control and anti-vaping push
Singapore Health Minister Ong Ye Kung receives SEATCA award for tobacco control and anti-vaping push
SEATCA has honoured Singapore Health Minister Ong Ye Kung with its inaugural Trailblazer Award, citing Singapore’s long-standing vaping ban, stepped-up enforcement and regulatory measures, and the city-state’s role in sharing tobacco-control policy experience across ASEAN.
Feb.06 by 2FIRSTS.ai
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam’s Government Decree 371, effective December 31, 2025, stipulates that users of e-cigarettes and heated tobacco products will be fined VND 3–5 million (about $114–$190) and required to destroy the products. The decree also provides that individuals who allow use at premises they own or manage will be fined VND 5–10 million (about $190–$380), with fines doubled for organizations.
Jan.04 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11